Roth Capital analyst Kyle Bauser resumed coverage of ARS Pharmaceuticals (SPRY) with a Buy rating and $30 price target The firm is anticipating significant revenue growth from the rapid adoption of the company’s signature product, neffy, which is an innovative intranasal epinephrine device for Type 1 allergic reactions, including anaphylaxis, the analyst tells investors in a research note. The ability of neffy to take significant share from outdated epinephrine auto-injectors is currently underappreciated, particularly given the recent sales growth to date, the firm added.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRY:
- Ars Pharmaceuticals’ Latest Study: A Potential Game-Changer in Allergy Treatment
- Ars Pharmaceuticals’ Promising Study on ARS-2 for Chronic Urticaria: What Investors Need to Know
- ARS Pharmaceuticals receives favorable decision from EPO on neffy
- ARS Pharmaceuticals: Strategic Financial Maneuvers and Market Potential Drive Buy Rating
- ARS Pharmaceuticals Secures $250 Million Credit Agreement